Pharmaceutical giant Eli Lilly and Co. agreed December 20 to pay $29.4 million to settle charges by the U.S. Securities and Exchange Commission that it violated the Foreign Corrupt Practices Act by making improper payments to officials in Russia, Brazil, China and Poland.
According to the SEC complaint filed in the U.S. District Court for the District of Columbia, Eli Lilly subsidiaries made payments to win millions of dollars of overseas business. Lilly did not admit or deny the allegations, but in a statement the company said it “believes that this civil settlement brings resolution to issues from the past and is in the best interest of the company.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]